Study wrapper · #817
Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.
Editor's note
A tightly scoped indirect treatment comparison examining whether oral semaglutide 25 mg and injectable (subcutaneous) semaglutide 2.4 mg deliver similar weight loss — a directly semaglutide-specific question with practical relevance to patients weighing pill versus injection. Bridging the OASIS 4 and STEP 1 placebo-controlled trials via a naive Bucher comparison, the authors report comparable efficacy across weight-change endpoints and responder thresholds, with any numerical differences well below the FDA's 5% threshold for clinical relevance and safety profiles broadly similar. The caveats are the standard ITC ones, and they matter: a naive Bucher approach assumes the two trials are exchangeable, which is never fully true, and the confidence intervals here straddle zero, so 'comparable' means 'no difference detected,' not 'proven identical.' The author affiliations point to manufacturer involvement. Still, the finding is coherent given the shared active molecule and similar systemic exposure. Solid, well-hedged formulation-comparison evidence for semaglutide.
Plain-language abstract
This study asked whether the pill form and the injectable form of semaglutide produce similar weight loss in adults with obesity. Since no trial has compared the two forms directly, researchers used a statistical method to bridge results from two separate placebo-controlled trials — one testing the daily 25 mg pill and one testing the weekly 2.4 mg injection. Across all the measures they looked at — average weight loss, the share of people reaching milestones like 5%, 10%, 15%, or 20% weight loss, and various health markers — the two forms performed about the same. Any small differences were well below the level regulators consider clinically meaningful, and side-effect profiles were broadly similar. The main limitation is that comparing across two different trials relies on the assumption that the trials are similar enough to compare, which is never perfectly true; the results showed no clear difference rather than proof that the two forms are identical. For patients choosing between a pill and an injection, this suggests weight-loss results may be broadly comparable.